An impaired intrinsic microglial clock system induces neuroinflammatory alterations in the early stage of amyloid precursor protein knock-in mouse brain

Junjun Ni¹*, Zhou Wu¹, Jie Meng¹, Takashi Saito², Takaomi C. Saida², Hong Qing³ and Hiroshi Nakanishi⁴*

Abstract

Background: Disturbances in clock genes affect almost all patients with Alzheimer's disease (AD), as evidenced by their altered sleep/wake cycle, thermoregulation, and exacerbation of cognitive impairment. As microglia-mediated neuroinflammation proved to be a driver of AD rather than a result of the disease, in this study, we evaluated the relationship between clock gene disturbance and neuroinflammation in microglia and their contribution to the onset of AD.

Methods: In this study, the expression of clock genes and inflammatory-related genes was examined in MACS microglia isolated from 2-month-old amyloid precursor protein knock-in (APP-KI) and wild-type (WT) mice using cap analysis gene expression (CAGE) deep sequencing and RT-PCR. The effects of clock gene disturbance on neuroinflammation and relevant memory changes were examined in 2-month-old APP-KI and WT mice after injection with SR9009 (a synthetic agonist for REV-ERB). The microglia morphology was studied by staining, neuroinflammation was examined by Western blotting, and cognitive changes were examined by Y-maze and novel object recognition tests.

Results: CLOCK/BMAL1-driven transcriptional negative feedback loops were impaired in the microglia from 2-month-old APP-KI mice. Pro-inflammatory genes in microglia isolated from APP-KI mice were significantly higher than those isolated from WT mice at Zeitgeber time 14. The expression of pro-inflammatory genes was positively associated with NF-κB activation and negatively associated with the BMAL1 expression. SR9009 induced the activation of microglia, the increased expression of pro-inflammatory genes, and cognitive decline in 2-month-old APP-KI mice.

Conclusion: Clock gene disturbance in microglia is involved in the early onset of AD through the induction of chronic neuroinflammation, which may be a new target for preventing or slowing AD.

Keywords: Clock genes, BMAL1, Microglia, APP-KI mice, Neuroinflammation, Alzheimer's disease

* Correspondence: nijunjun@dent.kyushu-u.ac.jp; nakanishi-h@yasuda-u.ac.jp
¹Department of Aging Science and Pharmacology, Faculty of Dental Sciences, Kyushu University, Fukuoka 812-8582, Japan
²Department of Pharmacology, Faculty of Pharmacy, Yasuda Women's University, Hiroshima 731-0153, Japan
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

McGeer and McGeer [1] suggested the pathological importance of neuroinflammation mediated by microglia rather than amyloid β (Aβ) in the pathogenesis of Alzheimer’s disease (AD), as anti-inflammatory agents have a substantial sparing effect on AD [2]. Although the neuroinflammation regularly observed in AD has long been incorporated into the amyloid cascade hypothesis of AD, two recent reports have suggested an inflammatory hypothesis for AD. Treatment with the colony-stimulating factor 1 receptor (CSF1R) inhibitors, that block microglial proliferation and rescue inflammatory alterations, improved the performance in memory and behavioral tasks without affecting the accumulation of Aβ in mouse models of AD [3, 4]. Furthermore, previous studies have provided evidence that infection of the brain with microbes is linked to AD [5, 6]. Some microbes can remain latent in the nervous system with the potential for reactivation, and neuronal damage caused by direct microbial action and microbe-induced inflammation might occur years after the initial infection. In line with this infection hypothesis of AD, we previously reported that virulence factors of Porphyromonas gingivalis, a major pathogen in periodontal disease, including lipopolysaccharide (LPS) and gingipains, were able to activate microglia to induce neuroinflammation through the activation of Toll-like receptor 2 and protease-activated receptor-2, respectively, [7, 8]. These observations suggest that excessive neuroinflammation mediated by microglia is a key driver of AD rather than a result of the disease.

Circadian rhythm disturbances have long been considered a consequence of neurodegeneration associated with AD. AD patients exhibit profound disruptions in their circadian rhythm concerning sleep-wakefulness and other processes. In the post-mortem brain tissue of AD patients, altered synchronization in the rhythms of clock gene expression, including period 1 (PER1), period 2 (PER2), and brain and muscle Arnt-like protein-1 (BMAL1), was noted in different regions of AD patients compared with control subjects [9]. The clock gene system is known to be capable of influencing the inflammatory process in a number of ways. BMAL1 is the central mediator of the circadian control of the immune system and promotes an anti-inflammatory state [10]. A recent clinical study showed that the significant deregulation of BMAL1 in the brain was associated with early AD [11]. An intrinsic molecular clock also exists in microglia that control diurnal morphological changes in their processes, and these cells regulate the sleep-wake cycle-dependent changes in synaptic strengths [12–14]. Furthermore, infection of P. gingivalis induced process extension of cortical microglia, and this response was significantly greater during the day than night [15], suggesting that the intrinsic microglial clock limits the overreaction and inflammatory responses of microglia during the active phase. However, little is known about the possible contribution of microglial intrinsic molecular clock to the neuroinflammatory response in AD pathology.

Although a number of AD mouse models have been developed based on amyloid precursor protein (APP) overexpression, the overexpression paradigm may cause additional phenotypes unrelated to AD, including the overproduction of soluble N-terminal fragments, C-terminal fragment-α, C-terminal fragment-β, and APP intracellular fragments [16]. To overcome these drawbacks, two novel AD mouse models (single humanized APP knock-in (KI) mice carrying Swedish (NL), Beyreuther/Iberian (F), or Arctic (G) mutations in different combinations) were generated by knock-in (KI) of a humanized Aβ sequence bearing AD-associated mutations into the mouse APP locus [17]. These models exhibit unique pathophysiological properties in the brain. For example, APP-KI NL-G-F/NL-G-F mice, which bear all three mutations, show aggressive Aβ pathology starting at 2 months of age [18].

We showed for the first time in the present study that a reduced expression level of BMAL1 was responsible for the increase in the inflammatory phenotype of microglia in APP-KI mice through a reduction in RORα, which in turn reduced IkBα and enhanced NF-κB activation. To determine the pathological roles of REV-ERB in the inflammatory response and learning ability of APP-KI mice, we evaluated the effects of SR9009, a synthetic agonist for REV-ERB, because REV-ERBα nuclear receptor plays a pivotal role in the negative feedback loop regulating the BMAL1 and CLOCK expression. These results suggest that an impaired intrinsic microglial clock system contributes to neuroinflammatory responses and the resultant cognitive impairment in the early stage of AD.

Methods

Animals

Wild-type (WT) and APP-KI mice on a C57BL/6 background were kept in a specific pathogen-free environment at Kyushu University Faculty of Dental Science. Under light-dark conditions, the Zeitgeber time 0 (ZT0) was designated as lights on and ZT12 as lights off. The line of APP-KI mice carried the Arctic mutation, Swedish, and Beyreuther/Iberian mutations. The selection of APP-KI homozygous mice from their littermates obtained by heterozygous coupling was performed by examining the template genomic DNA isolated from tail biopsies, using primers 5′-ATCTCGGAAGTGAAATG G-3′, 5′-ATCTCAGGATGAATGATGATGATAGTG-3′, 5′-TGAGAACTTAAC-3′, and 5′-CGTATAAATGATGC TATACGAAG-3′. Male mice were used in the whole study. Two-month-old WT and APP-KI mice were administered SR9009 (Millipore) 100 mg/kg (intraperitoneally) for
14 days. All animal experiments were conducted in accordance with the guidelines contained in the Act on Welfare and Management of Animals (Ministry of Environment of Japan) and Regulation of Laboratory Animals (Kyushu University) and under the protocols approved by the Institutional Animal Care and Use Committee review panels at Kyushu University.

**Immunoblotting analyses**
The brain cortical tissues were collected from APP-KI mice with or without SR9009 injection. The brain lysates were prepared as described previously [23]. The following primary antibodies were used: rabbit anti-Iba1 (1:1000; WAKO), mouse anti-NOS2 (1:1000; Abcam), mouse anti-IL-1β (1:1000, Santa Cruz Biotechnology), mouse anti-actin (1:5000; Abcam), mouse anti-phospho-IkBα (1:1000, Santa Cruz Biotechnology), rabbit anti-IkBα (1:1000, Santa Cruz Biotechnology), and mouse anti-Aβ (6E10, 1:1000, Covance). The following were used as secondary antibodies: horseradish peroxidase (HRP)-labeled anti-rabbit (1:2000; GE Healthcare) and anti-mouse (1:2000; R&D Systems). The HRP-labeled antibodies were detected using an enhanced chemiluminescence detection system (ECL Kit; GE Healthcare) with an image analyzer (LAS-1000; Fuji Photo Film).

**Real-time polymerase chain reaction (PCR)**
The mRNA isolated from the isolated microglia of each group at different time points were subjected to a real-time quantitative RT-PCR. The total RNA was extracted with the RNAiso Plus (Takara, Japan) according to the manufacturer’s instructions. A total of 1000 ng of extracted RNA was reverse transcribed to cDNA using the Quantitect Reverse Transcription Kit (Qiagen, Japan). After an initial denaturation step at 95 °C for 5 min, temperature cycling was initiated. Each cycle consisted of denaturation at 95 °C for 5 s, annealing at 60 °C for 10 s, and elongation for 30 s. In total, 40 cycles were performed. The cDNA was amplified in duplicate using a Rotor-Gene SYBR Green RT-PCR Kit (Qiagen, Japan) with a Corbett Rotor-Gene RG-3000A Real-Time PCR System. The data were evaluated using the RG-3000A software program (version Rotor-Gene 6.193, Corbett). The sequences of primer pairs were as follows:

- BMAL1: 5′-CTATCTTCCTGGACACTGC-3′ and 5′-CTTCTTGGCTCTGGAGAAG-3′; PER1: 5′-CCA-GATTTGCTGGGTTACTGAT-3′ and 5′-GCCGAGA GTCTTCTGGAGACGAT-3′; PER2: 5′-TTCCTACTA TGTGACAGGGAGG-3′ and 5′-CTATCCATTCATCA CTGTA-3′; REV-ERBα: 5′-CCCTGGACTCCA ATAACACACA-3′ and 5′-GCCATTGGAGCTGTCA CTGTA-3′; TNF-α: 5′-CTTAGCCACGCTCGTA GC-3′ and 5′-TTGAGATCCATGCCTGGT-3′; IL-1β: 5′-CAACCAAGTGTATTTCTCCATG-3′ and 5′-GATCCACACTCTCCAGCTGCA -3′; NOS2: 5′-GCCA CCAACATGGCAAC-3′ and 5′-CGTACGGGATGAG CTGTGAATT-3′; IL-6: 5′-TTCTAAAGCAAGGCT CGCTAGAG-3′ and 5′-AAGTACACGTTGTGGTTCTGAGT-3′; IkBα: 5′-GAAGCGCTGACCATGGAA-3′ and 5′-GATCACAGCCAAATGGGATGGA-3′; Actin: 5′-GAAGGGAATCTGTCGTGAC-3′ and 5′-CAATAG TGATGACCTTGCGGGT-3′.

For data normalization, an endogenous control (actin) was assessed to control for the cDNA input, and the relative units were calculated by a comparative Ct method. All of the real-time RT-PCR experiments were repeated three times, and the results are presented as the means of the ratios ± standard error of the mean (SEM).

**Cell isolation**
CD11b+ microglial cells were isolated from the mouse brain by the magnetic cell sorting (MACS) method as described previously [19]. Mice in each group were anesthetized and transcardially perfused with phosphate-buffered saline (PBS). The brains were separated as contralateral and ipsilateral samples and cut into small pieces. After enzymatic digestion using a Neural Tissue Dissociation Kit (Papain), the cell suspensions were further mechanically dissociated using a gentle MACS Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany). The single-cell suspensions were obtained after application to a 30-mm cell strainer. After magnetic labeling with CD11b Microbeads, the cell suspension was loaded onto a magnetic column placed in the magnetic separator (Miltenyi Biotec). The MACS column was then rinsed with PBS, and the CD11b-positive fraction was collected.

**Cell culture**
The mouse microglial cell line MG6 (Riken Cell Bank, RCB2403) was maintained in DMEM containing 10% fetal bovine serum (Gibco) supplemented with 450 mg/ml glucose (Gibco), penicillin-streptomycin (Gibco), 10 μg/ml insulin, and 100 μM β-mercaptoethanol in accordance with the previously described methods [20, 21]. They were synchronized by treatment with 100 nM dexamethasone (Wako) for 2 h and then stimulated with 10 μM SR9009 and 1 μM oligomeric Aβ (OAb) at the indicated time points. Non-synchronizing cells were treated with 50 ng/ml LPS (Sigma) or combination with 10 μM SR9009 for 8 h.

**CAGE RNA sequencing of microglia from WT and APP-KI mice**
ZT2 and ZT14 were 2 h after light turning on and turning off which can typically represent the day time and night time. Therefore, CD11b+ microglial cells were acutely isolated from WT and APP-KI mouse brain at
ZT2 and ZT14 by MACS methods, and then, 5 μg RNA of each group was prepared for sequencing. Cap analysis gene expression (CAGE) library preparation, sequencing, mapping, and gene expression were performed by DNA-FORM (Yokohama, Kanagawa, Japan). In brief, the RNA quality was assessed by a Bioanalyzer (Agilent) to ensure that the RNA integrity number (RIN) was over 7.0 and that the A260/A280 and 260/230 ratios were over 1.7. First-strand cDNAs were transcribed to the 5’ end of the capped RNAs and attached to CAGE “bar code” tags, and then, the sequenced CAGE was mapped to the mouse mm9 genomes using the BWA software program (v0.5.9) after discarding ribosomal or non-A/C/G/T base-containing RNAs. For tag clustering, the CAGE-tag 5’ coordinates were input for Reclu clustering, with a maximum irreproducible discovery rate (IDR) of 0.1 and minimum count per million (CPM) value of 0.1 [22].

Locomotor activity
Fourteen days after SR9009 treatment, locomotor activity was examined (day 15). Mice were removed from their home cages and placed in a novel home cage (clean and without bedding), which provided a floor area of 28 × 18 cm, and then, the locomotor activity of mice of each genotype and each different age group was scored for 3 min. The novel home cage was divided into six identical rectangles and a trained observer determined the incidence of line crossing.

Novel object recognition test
Fourteen days after SR9009 treatment, novel object recognition tests were examined (day 15–day 18). Mice were individually habituated to an open-field box (58 × 42 × 35 cm) by being given 10 min of exploration time in an empty arena for 3 days (habitation session). During the acquisition phase, two objects of the same material were placed in symmetrical positions at the center of the box for 10 min. One hour after the acquisition phase training, one of the objects was replaced with a novel object, and the exploratory behavior was again analyzed for 3 min. After each session, the objects were thoroughly cleaned with 75% ethanol to prevent odor recognition. Exploration of an object was defined as rearing on the object or sniffing it at a distance of <1 cm, touching it with the nose, or both. Successful recognition of a previously explored object was reflected by preferential exploration of the novel object. Discrimination of spatial novelty was assessed by comparing the difference between the time spent exploration of the novel and familiar objects and the total time spent exploring both objects, which made it possible to adjust for differences in total exploration time.

Y-maze test
Y-maze test was examined prior to Novel object recognition test on the same day (day 15). Testing occurred in a Y-shaped maze with three identical black Plexiglas arms at 120° angles from each other (40 × 10 × 20 cm; Shinfactory, Fukuoka, Japan). After being introduced to the end of one arm, the mice were allowed to freely explore the three arms in a 5-min session. The number of arm entries and the number of triads were recorded in order to calculate the percentage of alternation. The three consecutive choices were defined as an alternation. The percentage of alternations was calculated as (actual alternations/maximum alternations) × 100.

Immunofluorescent staining
Mouse brain samples for immunofluorescent staining were prepared as previously reported [20, 21]. Sections for staining were incubated with the following primary antibodies: rabbit anti Iba1 (1:2000, Wako) and mouse anti-Aβ (6E10, 1:1000, Covance) at 4 °C overnight. After being washed with PBS, the sections were incubated with donkey anti-rabbit Alexa 488 (1:500; Jackson ImmunoResearch) and donkey anti-mouse Cy3 (1:500; Jackson ImmunoResearch) at 4 °C for 2 h. After further washing, the sections were mounted in Vectashield antifading medium (Vector Laboratories). The fluorescence images were observed using a confocal laser scanning microscope (CLSM; C2si, Nikon).

Quantitative morphological analyses of microglia
Confocal Z stack images were captured from the brain of APP-KI mice with or without SR9009 injection. Somata of microglia were quantified after outlining using the ImageJ software program as reported previously [23]. The morphological analyses of microglia were performed using Z-projections of confocal images. Microglial processes were traced and reconstructed as a single microglia image using the Simple Neurite Tracer program, and the total process length was semi-automatically traced using three-dimensional image data. Single microglia with topological skeletonized images were converted using the skeletonize program.

Statistical analysis
The data are represented as the means ± SEM. The statistical analyses were performed by Student’s t test or a one- or two-way analysis of variance (ANOVA) with a post hoc Tukey’s test using the GraphPad Prism software package (GraphPad Software). A value of p < 0.05 was considered to indicate statistical significance. The significance, phase, and amplitude of 24 h rhythms in clock gene expression were evaluated statistically using the non-parametric JTK_Cycle test implemented in R [24].
Results

Aberrant diurnal clock gene rhythms in cortical microglia isolated from APP-KI mice

In order to clarify the mechanisms underlying the effects of diurnal clock genes on the pathology of AD, we performed CAGE RNA sequencing of microglia from a 2-month-old WT and APP-KI mice at ZT2 and ZT14. We identified 96,700 transcriptional start sites (TSS), 20% of which were upregulated (false discovery rate, FDR < 0.05, Log2Fc ≥ 1.5) and 19% of which were downregulated (FDR < 0.05, Log2Fc ≥ 1.5) at ZT2, 14% of which were upregulated, and 31% of which were downregulated at ZT14 in microglia from APP-KI mice compared to WT mice (Fig. 1a). A gene expression heatmap with blue-red representation of 10 clock genes obtained by the CAGE method was obtained for cortical microglia isolated from WT and APP-KI mice at ZT2 and ZT14 (Fig. 1b). Both REV-ERB and BMAL1 were under-expressed in cortical microglia isolated from 2-month-old WT and APP-KI mice at ZT14 relative to ZT2. In contrast, PER1 and PER2 were over-expressed in cortical microglia of both genetic groups at ZT14 relative to ZT2.

To verify these findings obtained by the CAGE method, the diurnal changes in the mean mRNA expression levels of BMAL1, REV-ERBa, PER1, and PER2 in cortical microglia prepared from WT and APP-KI mice were examined using quantitative PCR (qPCR). As reported previously [12], BMAL1 and REV-ERBa exhibited oscillations in cortical microglia isolated from WT mice with peaks at ZT2 and ZT10, respectively, (Fig. 1c, i). It is noted that the average values of mRNA expression of BMAL1 and REV-ERBa over the course of the day in APP-KI microglia were significantly lower than those in WT microglia (Fig. 1d, j). The WT cortical microglia also exhibited an oscillation of PER1 and PER2 with a peak at ZT18. In contrast, the expression of these clock genes in cortical microglia isolated from APP-KI mice showed differential oscillations as compared to those in WT microglia (Fig. 1e, g). BMAL1 and REV-ERBa exhibited oscillations with peaks at ZT22 and ZT6, respectively, whereas PER1 exhibited an oscillation with a peak at ZT6, and PER2 did not show a clear oscillation at all. The average value of mRNA expression of PER2 over the course of the day in APP-KI microglia was significantly lower than that in WT microglia, while there was no significant difference in the average value of mRNA expression of PER1 between the two groups (Fig. 1f, h). The rhythmicity in clock genes expression in microglia was further analyzed by JTK_CYCLE analysis (Additional file 1: Table S1). Taken together, these results suggest that the CLOCK/BMAL1-driven transcriptional negative feedback loops are impaired in the cortical microglia of APP-KI mice.

The comparative expression of inflammatory-related genes by microglia prepared from WT and APP-KI mice

To analyze the mRNA expression profiles of cortical microglia, we additionally used CAGE method for a gene ontology analysis. Figure 2a shows the heat map and hierarchical clustering of the transcripts in cortical microglia isolated from both WT and APP-KI mice at ZT2 and ZT14. The mRNA expression profile differed markedly between the cortical microglia isolated from different genetic groups. Interestingly, the gene ontology analysis indicated that the upregulated transcripts were significantly enriched for the inflammatory response, cell chemotaxis, and immune response in microglia from APP-KI relative to WT mice at ZT14 (Fig. 2b). The top 10 transcripts belonged to families involved in immune response as follows: nitric oxide synthase 2 (NOS2), serum amyloid A3 (Saa3), S100 calcium-binding protein A8 (S100a8), S100 calcium-binding protein A9 (S100a9), complement component 5a receptor 1 (C5ar1), Interleukin 1a (Ili1a), Interleukin 1 receptor antagonist (Il1ra), tumor necrosis factor receptor superfamily member 1A (Tnfrsf1a), C-X-C motif chemokine ligand 3 (Cxc3), and nuclear factor-κB1 (Nfkb1). In addition, the mean mRNA expression levels of these genes were significantly higher in cortical microglia isolated from APP-KI mice than in those from WT mice. Furthermore, the mean mRNA expression of these genes in cortical microglia isolated from APP-KI mice at ZT14 was significantly higher than those isolated at ZT2 (Fig. 2c).

Diurnal changes in the expression of inflammatory factors in cortical microglia isolated from WT and APP-KI mice

To validate the data obtained by the CAGE method, we quantified the mRNA expression of TNF-α, IL-1β, NOS2, and IL-6 in cortical microglia isolated from WT and APP-KI mice using qPCR. The expression of TNF-α, IL-1β, and IL-6 in cortical microglia isolated from APP-KI mice showed differential oscillations compared with those from WT microglia (Fig. 3a, c, g). In addition, TNF-α, IL-1β, and IL-6 in cortical microglia isolated from WT mice exhibited oscillations with peaks at ZT22, whereas their time of expression peak in microglia isolated from APP-KI mice was ZT14. No marked difference in the diurnal oscillation of the NOS2 expression was noted between the two groups (Fig. 3e). Furthermore, there was a significant increase in the average values of mRNA expression of TNF-α, IL-1β, and IL-6 over the course of the day in cortical microglia prepared from APP-KI mice as compared with those prepared...
from WT mice, but no difference was observed in the average value of mRNA expression of NOS2 between the two groups (Fig. 3b, d, f, h).

**Diurnal changes in the mRNA expression of IkBa and RORa in cortical microglia isolated from WT and APP-KI mice**

BMAL1 is known to drive the expression of RORα and thereby increase the transcription of IkBa, a major negative regulator of NF-κB. Therefore, we examined the possible diurnal changes in the mRNA expression of IkBa and RORα in cortical microglia isolated from WT and APP-KI mice. In CAGE analyses, the mean mRNA expression of IkBa and RORα in cortical microglia isolated from WT and APP-KI mice was significantly lower than in those isolated from WT mice at ZT14 (Fig. 4a, b). To verify the data obtained from the CAGE analysis, we conducted qPCR analysis in cortical microglia isolated from WT and APP-KI mice. In these qPCR analyses in cortical microglia isolated from WT mice showed oscillation of IkBa and RORα with a peak at
ZT18 (Fig. 4c, e). In contrast, the IκBα expression in cortical microglia isolated from APP-KI mice did not show a clear oscillation (Fig. 4c). The mean expression of RORα at ZT18 in APP-KI mice was significantly lower than that in WT mice (Fig. 4e). Furthermore, while there were no significant differences in the average values of mRNA expression of IκBα and RORα during the light phase between the two groups (Fig. 4d, f), significant differences were noted in the dark phase (Fig. 4d, f).

Given the above, we concluded that a reduced expression level of BMAL1 was responsible for the increased observation of the inflammatory phenotype of microglia in APP-KI mice through the reduction in RORα, which in turn decreased IκBα and subsequently enhanced NF-κB activation.

**Impairment of learning and memory in APP-KI mice by disturbing the intrinsic clock**

REV-ERBα nuclear receptor plays a pivotal role in the negative feedback loop regulating the BMAL1 and CLOCK expression [25, 26]. Therefore, it is likely that the excessive activation of REV-ERBα and subsequent reduction in the BMAL1 expression in microglia are responsible for the altered expression profiles of inflammatory mediators in microglia of APP-KI mice. To determine the pathological role of REV-ERBα in APP-KI mice, we investigated the effects of SR9009, a synthetic agonist for REV-ERBα, on the inflammatory response and learning ability of APP-KI mice.

A significant increase of REV-ERBα mRNA was detected in the cortex of APP-KI after treatment with SR9009 (Fig. 5a). Next, we examined the effects of SR9009 on the activation of microglia in APP-KI mice. The morphological changes in the microglia in the hippocampus of APP-KI mice were quantitatively analyzed before and after treatment with SR9009. Confocal laser scanning microscope (CLSM) images for Iba1 were traced as stack images and then reconstructed as skeletonized images of hippocampal microglia (Fig. 5b, c). These skeletonized images of hippocampal microglia revealed a significant shortening of their processes and no change of cell body size after treatment with RS9009.
Furthermore, the mean protein levels of Iba1, NOS2, and mature IL-1β in the hippocampus of APP-KI mice were significantly increased after treatment with SR9009 (Fig. 5f–i). At the same time, the mean phosphorylation level of IκBα in the hippocampus of APP-KI mice was also significantly increased after treatment with SR9009 (Fig. 5j, k).

The spontaneous locomotor activity was measured in APP-KI mice with or without SR9009 injection. SR9009 injection induced no significant change in the mean number of line-crossing in APP-KI mice (Fig. 5l). We then examined the effects of SR9009 on the cognitive ability using the Y-maze and novel object recognition tests, which are simple, commonly used tests for the assessing hippocampus-dependent learning and memory. Treatment with SR9009 induced no significant change in the mean number of entries into each arm in APP-KI mice (Fig. 5m). However, APP-KI mice treated with SR9009 showed a significantly lower percentage of alternations than the untreated mice (Fig. 5n). The WT and APP-KI mice showed a response to the novel object and were able to discern a change in the object (Fig. 5o). The same results were obtained in WT mice even after treatment with SR9009 (Fig. 5o). In contrast, APP-KI mice did not show a response and could not discern a change in the object after treatment with SR9009 (Fig. 5o).

**SR9009 aggravates the APP expression and soluble Aβ production in 2-month-old APP-KI mice**

To elucidate the mechanism underlying the SR9009-induced impairment of the novel object recognition in APP-KI mice, Aβ deposition and microglial activation were examined in the hippocampus and cerebral cortex of APP-KI mice. CLSM images showed that Aβ deposition and activated microglia at the site of Aβ deposition were observed in the hippocampus and cerebral cortex of 6-month-old, but not 2-month-old, APP-KI mice (Fig. 6a, b). We therefore further examined the possible deposition of monomeric Aβ in the cerebral cortex of 2-month-old APP-KI mice. Immunoblot analyses showed that treatment with SR9009 significantly increased the expression of both full-length APP and monomeric Aβ in the cortical lysate of 2-month-old APP-KI mice (Fig. 6c–e).
These effects of SR9009 in APP-KI mice prompted us to further examine a possible additive or synergistic effects of OAB and SR9009 on microglia, as SR9009 failed to induce either an inflammatory response or cognitive impairment in WT mice. MG6 microglia were synchronized by treatment with dexamethasone and then stimulated with OAB or combination with SR9009. Neither OAB nor SR9009 alone influenced the mean mRNA level of TNF-α, whereas the combination of OAB and SR9009 significantly increased the mean mRNA level of TNF-α (Fig. 6g). SR9009 alone significantly increased the mean mRNA levels of IL-1β and IL-6, whereas OAB alone had no effect on them. However, the combination of OAB and SR9009 further increased the mean mRNA levels of expression of IL-1β and IL-6 (Fig. 6f, h). In contrast, SR9009 significantly suppressed the mean mRNA expression levels of IL-1β and TNF-α in MG6 microglia stimulated with a high concentration of LPS (i.e., 50 ng/mL, Additional file 2: Figure S1).

The rhythmic expression of Bma1 and REV-ERBα was impaired by OAB in MG6 cells

To verify the neuroinflammation induced by combinatory treatment with OAB and SR9009 were triggered by a disturbance in clock genes. The relative mRNA expression of Bma1 and REV-ERBα was examined through the course of a single day after synchronization by Dex. The expression of BMAL1 and REV-ERBα showed no significant changes in the control group (Fig. 7a, c). However, BMAL1 and REV-ERBα showed the rhythmic changes and peaked at 18
and 24 h, respectively, after synchronization (Fig. 7a, c). To assess the effects of OAβ on BMAL1 and REV-ERBα expression in MG6 cells, their expression was examined 18 and 24 h, respectively, after treatment with OAβ following synchronization. OAβ significantly decreased the BMAL1 expression and increased the REV-ERBα expression (Fig. 7b, d), suggesting that OAβ did indeed disturb the circadian clock, at least in MG6 cells.

**Discussion**

There is increasing evidence that immune parameters change with the time of day and that disruption of the
circadian rhythms is linked to inflammatory pathologies. Previous studies have noted the importance of the circadian clock in age-related neuroinflammatory sensitization [27, 28]. BMAL1 is the central mediator of the circadian control of the immune system and anti-inflammatory system, as it drives the expression of RORα, which can increase the levels of IκBα [10, 29], a major negative regulator of NF-κB [30]. Furthermore, REV-ERBα is also a transcriptional repressor that inhibits the BMAL1 expression [26]. LPS-induced sepsis is less severe when injection at ZT10 than at ZT12, coinciding with a decrease in pro-inflammatory cytokines TNF-α, IL-6, and CXCL1 at ZT12, and increase in the anti-inflammatory cytokine IL-10. This effect is blunted a myeloid-specific BMAL1−/− mouse, indicating the anti-inflammatory role of BMAL1 in myeloid-lineage cells [31]. A recent report has demonstrated that activation of the NF-κB pathway in both primary microglia experiments and REV-ERBα−/− brain, demonstrating that REV-ERBα negatively controls microglial activation and neuroinflammation [32]. These observations are consistent with the previous observations that the NF-κB-mediated transcriptional repression of the clock feedback limb could cause circadian disruption in response to inflammation [33, 34]. These results suggest that REV-ERBα/BMAL1 is a regulator of microglial activation and neuroinflammation. However, little is known about the impairment of the intrinsic microglial clock in the early phase of AD. Furthermore, the involvement of an altered circadian clock gene expression in the increased presence of microglia with an inflammatory phenotype in AD remains poorly understood. To address these questions, we explored mRNA expression profiles of circadian clock genes and pro-inflammatory genes in cortical microglia isolated from 2-month-old APP-KI and WT mice using a combination of CAGE sequencing and q-PCR analyses. We first found that the mean mRNA expression of BMAL1 and REV-ERBα was
significantly lower in APP-KI microglia than in WT microglia. In contrast, the mean mRNA expression of pro-inflammatory genes, including TNF-α, IL-1β, and IL-6, at ZT14 was significantly higher in APP-KI microglia than in WT microglia. It was also noted that the diurnal mRNA expression of these pro-inflammatory genes was negatively associated with that of BMAL1. In contrast, the diurnal mRNA expression of IkBα was positively associated with that of BMAL1. Previous study reported that RORα inhibits NF-κB signaling by inducing IkBα gene expression [29]. We reported that chronic activation of NF-κB promoted increased expression of pro-inflammatory mediators including IL-1β, TNFα, and iNOS [21]. On the basis of these previous observations, it is likely to speculate that reduced expression of BMAL1 may promote the NF-κB activation and the subsequent increased expression of pro-inflammatory genes in APP-KI microglia.

A cross-sectional study had been conducted to examine the association between circadian function, aging, and preclinical AD pathology which included 189 cognitively normal participants. After correction for age and sex, the presence of preclinical amyloid plaque pathology, assessed by positive PiB imaging or increasing cerebrospinal fluid was associated with increased intradaily variability, suggesting preclinical AD is associated with rest-activity rhythm fragmentation and circadian dysfunction could contribute to the early pathogenesis of neurodegenerative disease [35]. In the present study, we used single humanized 2-month-old APP-KI mice. Compared to 6-month-old APP-KI mice, the 2-month-old mice did not exhibit Aβ deposition and activated microglia at the site of Aβ deposition in the hippocampus and cerebral cortex. Therefore, 2-month-old APP-KI mice were reasonable to be used to study the pathogenesis in the early stage of AD.
SR9009, which was developed as a synthetic REV-ERBα agonist, altered the circadian behavior and the circadian pattern of the core clock gene expression in the hypothalamus of mice [36]. Furthermore, LPS-induced IL-6 expression was attenuated in microglia from BMAL1-deficient mice. This phenotype was recapitulated by pharmacological disruption of oscillatory rhythmicity using SR9009 [37]. In a previous study, the REV-ERBα agonists, GSK4112, and SR9001 appeared to prevent neuroinflammation and cell death when infused into the brain [38]. These observations prompted us to examine whether or not the pharmacological activation of REV-ERBα could ameliorate neuroinflammatory response culminating in the disruption of learning and memory. The WT mice showed a response to the novel object and were able to discern a change in the object even after treatment with SR9009. Rather surprisingly, APP-KI mice did not show a response and could not discern a change in the object after treatment with SR9009, suggesting that pharmacological activation of REV-ERBα induced memory disruption in APP-KI mice but not in WT mice. On the other hand, SR9009 has been reported to have REV-ERB-independent proliferation and metabolism [39]. Therefore, additional experiments using REV-ERB deficient microglia are necessary to examine whether a memory impairment effect of SR9009 is due to an activation of REV-ERB.

It is interesting to speculate that OAβ enhances the effects of SR9009, as OAβ is generated even in the brain of 2-month old APP-KI mice. Furthermore, the APP expression is required for microglial activation, particularly in response to OAβ [40]. Our observations in the present study showed that treatment with SR9009 alone was able to increase the expression of IL-1β and IL-6 but not that of TNF-α in microglial cells. In contrast, OAβ failed to increase the expression of these pro-inflammatory genes. The combined treatment with SR9009 and OAβ significantly increased the TNF-α expression and further enhanced the expression of IL-1β and IL-6 in microglial cells. The present finding that OAβ significantly suppressed BMAL1 expression in microglia might suggest the possible involvement of decreased the BMAL1 expression and the subsequent activation of NF-κB in OAβ-induced neuroinflammation. Additional experiments will be needed to confirm this possibility. In the present study, systemic treatment with SR9009 induced activation of hippocampal microglia, increased expression of inflammatory mediators in the hippocampus, and memory disruption in APP-KI mice. SR9009 alone also increased the expression of IL-1β and IL-6 in MG6 microglia. The combined treatment with OAβ and SR9009 further increased expression of these cytokines. In contrast, Griffin et al. have reported that SR9009 exhibited dose-dependent suppression of LPS + ATP-induced IL-1β protein secretion in BV-2 cells and primary cultured microglia [32]. Moreover, an application of REV-ERBα agonist GSK4112 suppressed LPS-induced microglia activation through NF-κB pathway resulting in suppressing the expression and secretion of the pro-inflammatory cytokines [38]. In the present study, however, we could not see anti-inflammatory effects of SR9009. On the contrary, SR9009 induced pro-inflammatory mediators in both cultured microglia and the cerebral cortex of APP-KI mice. This discrepancy may stem from differences in experimental procedures. In our in vitro studies, MG6 microglia were synchronized by treatment with dexamethasone before treatment with SR9009. Dexamethasone was used in the concentration that does not induce anti-inflammatory effects. The inflammatory effect of SR9009 on cultured microglia corresponded well with our in vivo findings.

It has been reported that RORα can exert bi-directional regulation of IL-6 expression dependent on the activation state of astrocytes [41]. RORα may negatively regulate IL-6 expression through the NF-κB pathway in reactive astrocytes. On the other hand, RORα may transactivate IL-6 expression by interacting with a RORE in the promoter of non-reactive astrocytes. For these two pathways, RORα competes with REV-ERBα that binds the same response elements with a repressor activity. These observations prompted further examination of an anti-inflammatory effect of SR9009 on the strongly activated microglia, because Griffin et al. used a high concentration of LPS (i.e., 50 ng/mL) to activate microglia [32]. As shown in (Additional file 2: Figure S1), SR9009 exerted an anti-inflammatory effect on non-synchronizing and strongly activated MG6 microglia treated with LPS (50 ng/mL). Therefore, it is considered that SR9009 activates NF-κB pathway in synchronizing and mildly activated microglia through activation of REV-ERBα, while SR9009 may repress NF-κB in non-synchronizing and strongly activated microglia by interacting with RORE through activation of REV-ERBα. However, the exact action mechanism of SR9009 on microglia is to be elucidated in future studies.

Several recent reports suggest that circadian dysfunction has a causal role in AD-related neurodegeneration [42–44]. However, neuronal circadian dysfunction alone cannot fully explain the mechanistic relationship between circadian dysfunction and neurodegeneration, because neuroinflammation may play a crucial role in AD-related neurodegeneration [3, 4]. In the present study, we have found that microglia isolated from APP-KI mice exhibited circadian alterations that may be associated with excessive neuroinflammation. Therefore, it may be concluded that circadian disturbances of BMAL1/RORα/NF-κB crosslinking in microglia may contribute to the early stage of AD pathologies through induction of excessive neuroinflammation.
Conclusion

In summary, we found that microglial clock gene expression was disturbed in the early phase of APP-KI mice. The reduction expression of BMAL1 in the microglia from APP-KI mice at ZT14 or after SR9009 exposure was shown to be responsible for the increased presence of microglia with an inflammatory phenotype through a reduction in RORα, which in turn reduced IkBα and enhanced NF-kB activation. Therefore, microglial clock gene disturbance and resultant chronic neuroinflammation may contribute to the onset of AD.

Additional files

- Additional file 1: Table S1. JTK-Cycle analysis for 24h rhythmicity in clock gene expression in microglia. (DOCX 13 kb)
- Additional file 2: Figure S1. SR9009 suppressed the mean mRNA expression of IL-1β and TNF-α in MG6 microglia without synchronization. (DOCX 587 kb)

Abbreviations

AD: Alzheimer’s disease; ADJ.P: Adjusted p value; APP: Amyloid precursor protein; APP-KI: APP knock-in; Aβ: Amyloid beta; BMAL1: Brain and muscle Amt-like protein-1; C5ar1: COMPLEMENT component 5a receptor 1; CAGE: Cap analysis gene expression; CLOCK: Circadian locomotor output cycles kaput; CLSM: Confocal laser scanning microscope; CPM: Minimum count per million; CSF1R: Colony-stimulating factor 1 receptor; Cxcl3: C-X-C motif chemokine ligand 3; Orai: Orai1; IDR: Irreproducible discovery rate; IL1ra: Interleukin-1 receptor antagonist; IL1r1: IL1 receptor 1a; IL-1β: Interleukin-1β; IL-6: Interleukin-6; IkBα: Inhibitor of kBα; LPS: Lipopolysaccharide; MACs: Magnetic-activated cell sorting; NF-kB: Nuclear factor-kB; NOS2: Nitric oxide synthase 2; OAS: Oligomeric Aβ; PER1: Period 1; PER2: Period 2; REV-ERB: Nuclear receptor subfamily1 group D member 1; P2Y receptor: Retinoic acid receptor-related orphan receptor α; RT-PCR: Real-time PCR; S100a8: S100 calcium-binding protein A8; S100b9: S100 calcium-binding protein A9; Saa3: Serum amyloid A3; Tnf: Tumor necrosis factor receptor superfamily member 1A; TNF-α: Tumor necrosis factor-α; WT: Wild type; ZT: Zeitgeber time

Acknowledgements

We would like to thank Dr. Yuiro Takegami (DNAFORM Inc., Yokohama) for contributing to the generation of samples and analysis of the data set and thank Dr. Fumiko Takayama (Faculty of Dental Science, Kyushu University, Fukuoka) for CAGE data interpretation.

Authors’ contributions

JN conducted most of the experiments, analyzed the data, and wrote the manuscript. 2W and JM performed the cell isolation and RNA preparation. BS and TC provided APP-KI mice and valuable advice. HQ provided unpublished reagents/analytic tools. HN designed the whole study and wrote the manuscript. ZW and JM performed the cell isolation and RNA preparation. TS conducted most of the experiments, analyzed the data, and wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by JSPS KAKENHI Grant Numbers 18K19650 (a Grant-in-Aid for Challenging Research to H.N.) and JP17K17093 (a Grant-in-Aid for Young Scientists to J.N.).

Availability of data and materials

The data used in this study are available from the corresponding authors upon reasonable request.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Aging Science and Pharmacology, Faculty of Dental Sciences, Kyushu University, Fukuoka 812-8582, Japan. 2Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako 351-0198, Japan. 3Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Haidian District, Beijing 100081, People’s Republic of China. 4Department of Pharmacology, Faculty of Pharmacy, Yasuda Women’s University, Hiroshima 731-0153, Japan.

Received: 28 March 2019 Accepted: 20 August 2019

Published online: 30 August 2019

References

1. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126:479–97.
2. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405.
3. Olmos-Alonso A, Schetters ST, Sri S, Askew K, Mancuso R, Vargas-Caballero M, Holcher C, Perry VH, Gomez-Nicola D. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain. 2016;139:891–907.
4. Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MR, Bluntion-Jones M, West BL, Green KN. Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating amyloid-β pathology. Brain. 2016;139:1265–81.
5. Itzhaki RF, Craig RG, Dasanayake AP, Brys M, Giodzik-Sobanska L, de Leon MJ. Inflammation and Alzheimer’s disease: possible role of periodontal diseases. Alzheimers Dement. 2008;4:242–50.
6. Liu Y, Wu Z, Nakanishi Y, Ni J, Hayashi Y, Takayama F, Zhou Y, Kadowaki T, Nakanishi H. Infection of microglia with P. gingivalis promotes cell migration and an inflammatory response through the gingipain-mediated activation of pro tease-activated receptor-2 in mice. Sci Rep. 2017;7:11759.
7. Wu Z, Ni J, Liu Y, Teeling JL, Takayama F, Collcutt A, Ibbett P, Nakanishi H. Cathepsin B plays a critical role in inducing Alzheimer’s disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from Porphyromonas gingivalis in mice. Brain Behav Immun. 2017;65:350–61.
8. Gormakian N, Lamont EW, Boudreau P, Bolvin DB. Circadian clock gene expression in brain regions of Alzheimer’s disease patients and control subjects. J Biol Rhythm. 2011;26:160–70.
9. Curtis AM, Bellet MM, Sassone-Corsi P, O’Neill LA. Circadian clock proteins and immunity. Immunity. 2014;40:78–86.
10. Cronin P, McCarthy MJ, Lim ASP, Salmon DP, Galasko D, Mosiah E, De Jager PL, Bennett DA, Desplats P. Circadian alterations during early stages of Alzheimer’s disease are associated with aberrant cycles of DNA methylation in BMAL1. Alzheimers Dement. 2017;13:689–700.
11. Hayashi Y, Koyanagi S, Kusunose N, Takayama F, Okada R, Wu Z, Tozaki-Saitoh H, Uki K, Kohsaka S, Inoue K, Ohdo S, Nakanishi H. The intrinsic microglial molecular clock controls synaptic strength via the circadian expression of cathepsin S. Sci Rep. 2013;3:2744.
12. Hayashi Y, Koyanagi S, Kusunose N, Takayama F, Okada R, Wu Z, et al. Diurnal spatial rearrangement of microglial processes through the rhythmic expression of P2Y<sub>12</sub> receptors. Neurol Dis Ther. 2013;1:2.
13. Takayama F, Zhang X, Hayashi Y, Wu Z, Nakanishi H. Dysfunction in diurnal synaptic responses and social behavior abnormalities in cathepsin S-deficient mice. Biochem Biophys Res Commun. 2017;490:447–52.
14. Takayama F, Wu Z, Liu Y, Nakanishi H. Diurnal dynamic behavior of microglia in response to infected bacteria through the UDP-P2Y<sub>6</sub> receptor system. Sci Rep. 2016;6:30006.
15. Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad P, Saito KD. APP mouse models for Alzheimer’s disease preclinical studies. EMBO J. 2017;36:2473–87.
17. Saito T, Matsuba Y, Miura N, Takano J, Nilsson P, Itohara S, Iwata N, Saito TC. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci. 2014;17:661–3.

18. Nilsson P, Saito T, Saito TC. New mouse model of Alzheimer’s. ACS Chem Neurosci. 2014;5:499–502.

19. Wu Z, Sun L, Hashioka S, Yu S, Schwab C, Okada R, Hayashi Y, McGeer PL, Nakashima H. Differential pathways for interleukin-1β production activated by chromogranin A and amyloid beta in microglia. Neurobiol Aging. 2013;34:2715–25.

20. Ni J, Wu Z, Toka V, Meng J, Hayashi Y, Peters C, Qing H, Turk V, Nakashima H. Increased expression and altered subcellular distribution of cathepsin B in microglia induce cognitive impairment through oxidative stress and inflammatory response in mice. Aging Cell. 2019;18:e12856.

21. Ni J, Wu Z, Peters C, Yamamoto K, Qing H, Nakashima H. The critical role of proteolytic relay through cathepsins B and E in the phenotypic change of microglia/macrophage. J Neurosci. 2015;35:12488–501.

22. Ohmiya H, Vitezic M, Frith MC, Itoh M, Carninci P, Forrest AR, Hayashizaki Y, Lassmann T, Consortium F. RECLU: a pipeline to discover reproducible transcriptional start sites and their alternative regulation using capped analysis of gene expression (CAGE). BMC Genomics. 2014;15:269.

23. Sun L, Wu Z, Hayashi Y, Peters C, Tsuda M, Inoe K, Nakashima H. Microglial cathepsin B contributes to the initiation of peripheral inflammation-induced chronic pain. J Neurosci. 2012;32:11330–42.

24. Hughes ME, Hogenesch JB, Kornacker K. JTK_CYCLE: an efficient nonparametric algorithm for detecting rhythmic components in genome-scale data sets. J Biol Rhythm. 2010;25:372–80.

25. Crumley C, Büris TP. Direct regulation of CLOCK expression by REV-ERB. PLoS One. 2011;6:e17290.

26. Preitner N, Damiola F, Lopez-Molina L, Zakany J, Duboule D, Albrecht U, Schibler U. The orphan nuclear receptor REV-ERBα regulates circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251–60.

27. Fonken LK, Frank MG, Kitt MM, Barrientos RM, Watkins LR, Maier SF. Microglial inflammatory responses are controlled by an intrinsic circadian clock. Brain Behav Immun. 2015;45:171–9.

28. Fonken LK, Kitt MM, Gaudet AD, Barrientos RM, Watkins LR, Maier SF. Diminished circadian rhythms in hippocampal microglia may contribute to age-related neuroinflammatory sensitization. Neurobiol Aging. 2016;47:102–12.

29. Delerive P, Monte D, Dubois G, Trottein F, Fruchart-Najib J, Mariani J, Lassmann T, Consortium F. RECLU: a pipeline to discover reproducible transcriptional start sites and their alternative regulation using capped analysis of gene expression (CAGE). BMC Genomics. 2014;15:269.

30. Sun L, Wu Z, Hayashi Y, Peters C, Tsuda M, Inoe K, Nakashima H. Microglial cathepsin B contributes to the initiation of peripheral inflammation-induced chronic pain. J Neurosci. 2012;32:11330–42.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.